Correction to “Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy” (Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy (2013) 8(2) (118–127), (S1818087613000160), (10.1016/j.ajps.2013.07.015));Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 2, 2013, Pages 118-127

  Wang, Chenyu ^a   Feng, Linglin ^c   Yang, Xiangkun ^a   Wang, Fei ^a   Lu, Weiyue ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Department of Macromolecular Science   (China)

^c SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

Folic acid; Liposome; Multidrug resistance; Pharmacodynamics; Targeting delivery; Vincristine

Indexed keywords

FOLIC ACID; LIPOSOME; MACROGOL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84881328645     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2022.07.001     Document Type: Erratum

References (26)

1. Xiao L, Xiong XQ, Sun XH, et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials. 2011, 32: 5148-5157.
2. Dong XW, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine. 2010, 5: 597-615.
3. Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein Using Immunoliposomes. Journal of Drug Targeting. 2002, 10: 73-79.
4. Soma CE, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000, 21: 1-7.
5. Steiniger SCJ, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer. 2004, 109: 759-767.
6. Liu Z, Wu XY, Bendayan R. In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells. Journal of Pharmaceutical Sciences. 1999, 88: 412-418.
7. Cheung RY, Ying Y, Rauth AM, et al. Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C. Biomaterials. 2005, 26: 5375-5385.
8. De Verdiere AC, Dubernet C, Nemati F, et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer. 1997, 76: 198-205.
9. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers for overcoming drug resistance in cancer. Advanced Drug Delivery Reviews. 2002, 54: 759-779.
10. Yan Z, Wang F, Wen Z, et al. LyP-1-conjugated PEGylated liposomes: A carrier system for targeted therapy of lymphatic metastatic tumor. Journal of Controlled Release. 2012, 157:118-125.
11. Lecanda F, Warlow PM, Halstead LR, et al. Impaired intramembranous bone formation in connexin43 null mice. Bone. 1998, 23: S149-S653.
12. Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1993, 1151: 201-215.
13. Xiaohong Zhang, Furong Zhang, Xiujuan Ji, et al. Vincristine-resistant Human KB Cell Line and Mechanism of Multidrug Resistance. Acta Pharmaceutica Sinica. 1994, 29: 246-251.
14. Aronov O, Horowitz AT, Gabizon A, et al. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug Chem. 2003, 14:563-574.
15. Hsu H-K, Yang R-C, Shih H-C, et al. Prenatal Exposure of Testosterone Prevents SDN-POA Neurons of Postnatal Male Rats From Apoptosis Through NMDA Receptor. Journal of Neurophysiology. 2001, 86: 2374-2380.
16. Simões S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews. 2004, 56: 947-965.
17. Gerweck LE, Seetharaman K. Cellular pH Gradient in Tumor versus Normal Tissue: Potential Exploitation for the Treatment of Cancer. Cancer Research. 1996, 56: 1194-1198.
18. Aluri S, Janib SM, Mackay JA. Environmentally responsive peptides as anticancer drug carriers. Advanced Drug Delivery Reviews. 2009, 61: 940-952.
19. J.F. Ross, P.K. Chaudhuri, M. Ratnam. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications, Cancer. 1994, 73:2432-2443.
20. G. Toffoli, A. Russo, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. International Journal of Cancer. 1998, 79: 121-126.
21. J.A. Reddy, P.S. Low. Folate-mediated targeting of therapeutic and imaging agents to cancers, Critical Reviews in Therapeutic Drug Carrier Systems. 1998, 15: 587-627.
22. Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. European Journal of Pharmaceutical Sciences. 2009, 37: 300-305.
23. Barthomeuf C, Grassi J, Demeule M, et al. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemotherapy and Pharmacology. 2005, 56: 173-181.
24. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22: 7468-7485.
25. Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. International Journal of Cancer. 2003, 103: 587-599.
26. Gong Y, Duvvuri M, Krise JP. Separate Roles for the Golgi Apparatus and Lysosomes in the Sequestration of Drugs in the Multidrug-resistant Human Leukemic Cell Line HL-60. Journal of Biological Chemistry. 2003, 278: 50234-50239.